The worlds largest antihypertensive drugs test
Posted by sldol on October 31, 2008 in Venereal Disease
Began in June 1998, a five-year global field of cardiovascular treatment of the largest clinical trial - VALUE trial (Valsartan control of hypertension treatment and assessment of long-term test) for February 28, 2000 in London announced This far-reaching significance of the trial has reached the 32 countries in over 1,000 centres to group the goal of 15,000 patients. VALUE trial is a prospective, multinational, multi-center, double-blind, randomized controlled trials, to compare the World Health Organization recommended a new first-line antihypertensive drugs - angiotensin II receptor blocker (ARB) representatives Drugs “and the text” and a very broad application of the calcium channel blocker (CCB) amlodipine reduced cardiovascular events (such as myocardial infarction) the incidence of and mortality. May 27, 1998, approved by the Ministry of Health, China’s 10 well-known hospitals on behalf of the Asian countries participated in the VALUE trial. February 28 this year, Mar. 2, from China’s Shanghai Ruijin, Huashan, Beijing Chaoyang Hospital and the People’s Hospital of the five leading cardiovascular experts were invited to attend the third held in London the angiotensin II receptor antagonists International Academic Conference. VALUE trial will determine whether the text of the same blood pressure control, under the premise of reducing acute myocardial infarction, congestive heart failure and cardiac mortality provide more significant effect. The results showed that by selectively blocking angiotensin receptor IIAT1, the inhibition of angiotensin II, played the role of cardiovascular damage, but did not block AT2 receptor while retaining its useful role in that increase Coronary flow increased myocardial protection and increase anti-proliferation. Therefore, the text is expected to achieve effective control of blood pressure and lower overall cardiovascular morbidity and mortality of the ideal role. In the third angiotensin II receptor antagonists international academic conference, the U.S. National Heart Research Center of the expert report of Dr. JoelNeutel, in clinical trials found that the text can effectively reduce the use of other drugs to control blood pressure. June 12, 1999 in Milan at the European Society of Hypertension meeting, the University of Pavia, Italy, Professor RobertoFogari also announced that, through the age of 94 men between the ages of 40-49 in patients with hypertension conducted a randomized, double-blind, Cross-test results show that the text of the male patients with hypertension and activities in promoting the role. He pointed out: “This result, for those who worry that anti-hypertension drugs will affect their sexual function in male patients with hypertension is good news.” According to statistics, the current global hypertension patients has reached 500 million, China’s incidence rate is as high as 14 percent, high blood pressure caused by stroke and other cardiovascular diseases have become China’s urban residents died because of the first. “Generation text” (valsartan) is the Novartis Research and Development of a new generation of highly effective anti-hypertensive drugs. Since 1996 the first in Germany and other European countries listed have been more than 70 countries around the world successful listing, known as the ideal anti-hypertensive drugs. June 1999, Beijing Novartis Pharmaceutical Co., Ltd. will introduce the Chinese market the drug. Because of its outstanding relief performance and excellent security, in early 1999, the World Health Organization has officially “generation,” this new type of antihypertensive drugs as the world’s first anti-hypertensive drugs.
Subscribe
Follow comments by subscribing to the The worlds largest antihypertensive drugs test Comments RSS feed.